Xiaomou Wei

1.1k citations
14 papers · 890 · 1 hit paper · h-index 9

Impact in

    • MicroRNA in disease regulation
    • Cancer-related molecular mechanisms research
    • Extracellular vesicles in disease
    • RNA Interference and Gene Delivery
    • Circular RNAs in diseases
    • RNA modifications and cancer

Papers in

    • RNA modifications and cancer 3
    • Circular RNAs in diseases 2
    • Immune Cell Function and Interaction 3
    • Immunotherapy and Immune Responses 2

Xiaomou Wei

14 papers receiving 879 citations

Xiaomou Wei's Hit Papers

Phase I Clinical Trial of Autologous Ascites-derived Exosomes Combined With GM-CSF for Colorectal Cancer 2008 · 683 citations
6830+6+12Years since publication200400600

Peers

Xiaomou Wei
Comparison fields: 5 of 75
  • Cancer Research 438
  • Molecular Biology 719
  • Immunology 165
  • Immunology and Allergy 18
  • Biomaterials 34
Replace Yangzhou Su with:
Yangzhou Su China
Omnia M. Elsharkasy Netherlands
Ola A. Elgamal United States
Travis J. Antes United States
Jerney J. Gitz-Francois Netherlands
Xinming Yin China
Tin Chanh Pham Hong Kong
Ilgin Kimiz‐Gebologlu Türkiye
Victor Ma China
Xiaomou Wei relative to Yangzhou Su China Yangzhou Su's profile →
Citations per field
00.5×12.4×
Yangzhou Su · 1×
Citations per year

Countries citing papers authored by Xiaomou Wei

Since Specialization
Citations

This map shows the geographic impact of Xiaomou Wei's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Xiaomou Wei with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Xiaomou Wei more than expected).

Fields of papers citing papers by Xiaomou Wei

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Xiaomou Wei. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Xiaomou Wei. The network helps show where Xiaomou Wei may publish in the future.

Co-authors

The 25 scholars most cited alongside Xiaomou Wei, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Xiaomou Wei Line = papers co-authored together Xiaomou Wei links everyone, so they are left out of the graph.

All Works

14 of 14 papers shown
#Work
1
Phase I Clinical Trial of Autologous Ascites-derived Exosomes Combined With GM-CSF for Colorectal Cancer
Hit paper breakdown →
2008683
2 201549
3 201734
4 201820
5 201420
6 200916
7 202014
8 201614
9 201814
10 20168
11 20146
12 20215
13
LncRNA TGFB2-AS1 regulates lung adenocarcinoma progression via act as a sponge for miR-340-5p to target EDNRB expression.
20205
14 20162

About Xiaomou Wei

Xiaomou Wei is a scholar working on Molecular Biology, Immunology, Cancer Research, Oncology and Biomedical Engineering, having authored 14 papers that have together received 890 indexed citations. Recurring topics across this work include Immune Cell Function and Interaction (3 papers), RNA modifications and cancer (3 papers), Cancer-related molecular mechanisms research (3 papers), Immunotherapy and Immune Responses (2 papers), Circular RNAs in diseases (2 papers), Bone Tissue Engineering Materials (2 papers), Metal and Thin Film Mechanics (1 paper) and Lung Cancer Research Studies (1 paper). The work is most often cited by research in Cancer Research (438 citations), Molecular Biology (719 citations), Immunology (165 citations), Immunology and Allergy (18 citations) and Biomaterials (34 citations). Xiaomou Wei has collaborated with scholars based in China and United States. Frequent co-authors include Shengming Dai, Dong Wei, Xiangyang Zhou, Zhen Wu, Guisheng Li, Haixin Huang, Wei Liang, Bing Li, Haobo Pan and Xuan Zhu. Their work appears in journals such as Disease Markers, Tumor Biology, Molecular Biology Reports, Oncotarget and Journal of Biomedical Materials Research Part B Applied Biomaterials.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact